SmiLe Incubator

Yazen is a digital healthcare provider focused on delivering personalized weight loss programs, primarily targeting middle-aged men dealing with obesity and potential testosterone deficiencies. The company connects users with a multidisciplinary team of professionals, including doctors, psychologists, dietitians, and personal trainers, to develop customized weight management plans. By leveraging data-driven insights, Yazen incorporates lifestyle changes and, when necessary, medical treatments to enhance both physical and mental well-being. The platform's holistic approach aims to empower individuals to achieve sustainable health improvements through expert guidance and support.

Call Knut is a developer of communication software focused on monitoring elderly individuals, particularly those with chronic diseases. The company offers an artificial intelligence-based eHealth care platform that facilitates phone calls and initiates automated conversations with elderly users. This technology allows caregivers to assess the recipient's voice and identify potential medical warning signals, promoting a more effective and less intrusive approach to elderly care. By leveraging advanced communication tools, Call Knut aims to enhance the well-being and safety of senior citizens.

Saveggy is a company focused on creating bio-based edible coatings for fruits and vegetables, aimed at eliminating plastic packaging while maintaining protective properties. By offering an innovative and sustainable alternative, Saveggy's products help reduce food loss and waste throughout the supply chain. The company's technology is fully scalable and complies with EU regulations for edible coatings, making it a unique solution for fruits and vegetables with edible peels. This approach not only supports sustainability efforts but also ensures that more food can reach consumers, addressing key challenges in food distribution and waste.

Manje Health is a search and discovery platform for chronic disease treatment.

Xaga Surgical focuses on developing innovative medical needles designed to minimize the risk of infections associated with their use. The company's products aim to significantly reduce the risk of severe sepsis by virtually eliminating bacterial transfer during needle insertion. This advancement enhances safety not only in the diagnosis of prostate cancer but also in various other medical applications, ultimately helping patients lower their chances of developing severe infections.

TIGERQ is a provider of gene editing analysis services focused on accelerating biomedical innovation. The company specializes in a sample-to-analysis solution that integrates proprietary sequencing algorithms with efficient and cost-effective sample processing. By leveraging the CRISPR-Cas9 gene editing method, TIGERQ aims to assist drug researchers in reducing the lead time required for developing new medicines and vaccines. Their offerings are designed to enhance the speed and efficacy of biomedical research, ultimately contributing to advancements in healthcare.

Syntaxis is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke.

In2cure is a biotechnology company focused on developing peptide-based drugs aimed at preventing and treating inflammatory diseases and infections. The company leverages scientific discoveries related to natural host defenses to create novel therapies. In2cure specializes in peptides that possess anti-endotoxic properties, utilizing sequences that are identical to protein fragments naturally found in the human body. This approach allows for the production of anti-inflammatory drugs that are less toxic and more easily soluble, promoting the generation of healing peptides during instances of wounding and inflammation. Through its innovative research, In2cure strives to contribute to more effective and safer therapeutic options in the field of medicine.

Thyrolytics specializes in the development of an innovative diagnostic device that measures serum levels of free T4 and T3, key thyroid hormones. Utilizing advanced nanotechnology and protein engineering, the company offers a reliable and cost-effective point-of-care solution for monitoring thyroid hormone levels in the blood. This technology aims to enhance the management of thyroid health, providing users with a straightforward method to ensure their thyroid function is maintained effectively.

ReceptorPharma is a drug discovery company focused on developing innovative treatments for Alzheimer's disease and other debilitating conditions, including certain types of cancer. The company employs a novel mechanism of action that targets G-protein-coupled receptors to create therapies aimed at reversing disease progression. Specifically, ReceptorPharma concentrates on patients with early-stage Alzheimer's who retain their cognitive abilities, seeking to improve their quality of life through effective pharmaceutical interventions.

Bionamic offers a data management platform designed to streamline the analysis of life science data, particularly in biopharma research and development. The platform acts as a centralized resource for antibody-related discovery and development data, allowing researchers to efficiently navigate and comprehend their data. By minimizing or eliminating manual processes between raw data and results, Bionamic enhances decision-making capabilities for researchers, ultimately contributing to advancements in the biopharmaceutical sector.

SAGA Diagnostics AB is a company specializing in molecular genetic tests and services aimed at enhancing cancer diagnostics and disease monitoring for healthcare providers, biopharmaceutical firms, and academic institutions. Founded in 2016 as a spin-out from a research group at Lund University, SAGA focuses on the analysis of circulating tumor DNA (ctDNA), a critical biomarker for cancer. The company offers a range of services, including gene mutation analysis, chromosome analysis, and non-invasive liquid biopsy testing, which allows for the ultrasensitive detection of actionable mutations. SAGA's proprietary technology supports oncologists and drug developers by enabling the stratification of patient groups and monitoring treatment responses, thereby facilitating more precise cancer medicine and improving patient outcomes. Based in Lund, Sweden, SAGA is driven by a team of experienced scientists and professionals dedicated to advancing cancer research and clinical diagnostics.

Medow is a company focused on creating innovative healthcare products that enhance patient comfort and improve efficiency in medical settings. One of its key offerings is a reusable medical bracelet designed to securely hold intravenous tubes in place during treatments. This slap-on bracelet ensures that the intravenous needle remains stable throughout the procedure, significantly reducing the need for nurses to frequently reattach tape or insert new needles. By prioritizing design and functionality, Medow aims to make healthcare experiences more pleasant for patients while optimizing the workflow for healthcare professionals.

Medotemic AB, founded in 2016 and based in Lund, Sweden, specializes in developing innovative solutions for analyzing gait deviations, particularly those resulting from injuries or pain. The company's main product, Medomotion, is a mobile application that leverages smartphone sensor data to provide objective analysis of movement patterns during walking and running. By utilizing proprietary algorithms, Medotemic offers detailed insights into gait deviations, enabling users to measure and improve their movement through personalized training plans. The application also facilitates remote monitoring for both consumers and healthcare professionals, providing immediate feedback that can enhance treatment and recovery processes. Through its technology, Medotemic aims to increase awareness and motivate users to adhere to their rehabilitation programs.

POOW Applications has developed The Food Hero app that helps children with different types of eating disorders.

Gedea Biotech AB, founded in 2015 and based in Lund, Sweden, focuses on developing an antibiotic-free treatment for vaginal fungal infections, a common issue affecting approximately 75% of women at some point in their lives. The company's key product, GA101, utilizes natural substances to lower vaginal pH, provide physical barrier protection, and inhibit biofilm formation. This innovative approach aims to offer a safe and effective solution for treating and preventing vaginal infections without the use of antibiotics. Gedea Biotech is committed to addressing women's health needs through its unique treatment options.

Truly Labs specializes in providing customized in vitro and in vivo services aimed at enhancing drug delivery and biomarker analysis. The company employs established kits to conduct comprehensive biomarker analysis, integrating these efforts into pharmacology programs. Their focus is on designing and executing tailored studies that supply essential information for preclinical development and clinical design. By serving large pharmaceutical and biotech companies, Truly Labs plays a crucial role in advancing the drug development process.

Cellevate AB is a biotech company based in Lund, Sweden, founded in 2014. It specializes in developing advanced 3D cell culture systems utilizing nanofiber scaffolds known as 3D NanoMatrix. These scaffolds facilitate the creation of realistic in-vitro models, which are essential for scientific research and development across various fields, including automotive, construction, defense, electronics, energy, environment, and healthcare. Cellevate's platform employs a patented manufacturing process to produce consistent and porous networks of nanofibers, enhancing the effectiveness of cell culture systems and supporting upstream bioprocessing efforts.

MedVasc is a company focused on developing innovative medical devices aimed at improving the treatment of varicose veins. It has created a patented device designed to enhance the anesthetic procedure, significantly reducing pain during treatment. By introducing advanced technology to the healthcare industry, MedVasc aims to improve patient comfort and outcomes in varicose vein treatments.

Speximo AB, founded in 2012 and based in Lund, Sweden, specializes in developing starch-based emulsifiers derived from quinoa for surfactant-free emulsions. The company operates in the cosmetics, pharmaceutical, and food industries, providing sustainable solutions for the stabilization of oil-water-based products. Speximo’s patented technology allows for the encapsulation of active ingredients, ensuring stable formulations while enhancing the texture of end products. The company collaborates closely with researchers from Lund University and Malmö University to advance its understanding of starch Pickering emulsions and explore new applications. Since 2013, Speximo has been located in Medicon Village, where it focuses on solving formulation challenges and innovating environmentally friendly alternatives in product development. As of September 2019, Speximo operates as a subsidiary of Lucas Meyer Cosmetics Canada, Inc.

SARomics Biostructures AB, founded in 2006 and based in Lund, Sweden, provides a comprehensive range of structural biology and structure-based drug discovery services to biotech and pharmaceutical companies, as well as non-profit institutions globally. The company's offerings include crystallography and NMR spectroscopy services, encompassing protein crystallization, structure determination, and ligand binding assays. Additionally, SARomics specializes in gene-to-structure services that involve protein cloning, expression, purification, and structural analysis. Its expertise extends to kinase structures and fragment-based drug discovery, along with structure-based drug discovery services that facilitate hit identification and lead optimization. The company also provides computational chemistry and contract drug discovery services, focusing on optimizing protein structures and activities. By supplying essential insights into the interactions between drug substances and target molecules, SARomics aids in the efficient development of new pharmaceuticals.